Rocket Pharmaceuticals is a Buy, with strong catalysts, undervalued programs, and significant upside. Click here to read my ...
Orpha Labs AG today announced its compassionate use program to make ORL–101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel ...
Experts on agra-rian reform and rural development made a forecast on the post-land acquisition and distribution (LAD) program of the Com-prehensive Agrarian Reform Program (CARP). Contained in a ...
THE NEW regional director of the Department of Agrarian Reform (DAR) in Cagayan Valley (Region 2), Samuel S. Solomero, has vowed to expedite the land acquisition and distribution (LAD) program in line ...
First Patient to Receive ORL-101 in Israel This Week BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL-101 available to physicians ...